Innovex (INVX) Q1 2025 Earnings Call Transcript

Innovex reported Q1 revenue of $240 million, up 88% year over year but down 4% sequentially, with adjusted EBITDA of $46 million and free cash flow of $24 million. Margins improved to 19% EBITDA margin from 18% at the time of the Dril-Quip merger, while management flagged weak Mexico activity, delayed offshore deliveries, and cautious Q2 guidance of $225 million-$235 million revenue and $40 million-$45 million adjusted EBITDA. The company also announced a definitive agreement to sell the Eldridge facility for $95 million and repurchased about $6 million of stock, supporting its capital-return and restructuring story.

Analysis

INVX is in the awkward middle of the cycle where fundamentals are improving underneath noisy revenue. The key second-order read is that management is intentionally sacrificing reported smoothness for better cash conversion: the move to delivery-based accounting should depress near-term revenue visibility but improve earnings quality, working capital discipline, and the eventual multiple if they can keep execution on-time. That matters because the market will likely punish the next 1-2 quarters of lumpiness before it rewards the cleaner backend economics.

The bigger strategic catalyst is the balance-sheet story, not the quarter. A near-10% of market cap asset sale plus ongoing FCF creates a self-funding capital allocation loop: buybacks become a floor in weak tape, while M&A optionality improves exactly as sector sellers get more stressed. The likely winners are small, PE-backed niche tool businesses and regional distributors that need scale; the losers are subscale competitors that cannot absorb tariff volatility, integration CapEx, or delivery-performance scrutiny. If Mexico stays depressed, that weakness may also free up field teams and inventory for higher-return geographies, creating hidden margin support.

Consensus seems too focused on the revenue miss and not focused enough on operating leverage in the installed base. The market may be underestimating how quickly a few incremental points of on-time delivery and facility consolidation can re-rate EBITDA margins into the low/mid-20s even without top-line growth. The contrarian risk is that U.S. land slows harder than management is modeling; if that happens, buybacks become less accretive and the stock may need one more reset before the cash-rich thesis works. Time horizon matters: near-term downside is 1-2 quarters of guide skepticism, but 6-18 months out the setup improves if sub-$60 oil compresses sector capital and INVX converts that into acquisitions or repurchases at depressed valuations.

Key Decisions for Investors

• Buy INVX on weakness in the next 1-2 weeks, using a staggered entry; target 12-18 months. Risk/reward: limited balance-sheet risk and visible capital return optionality versus near-term guide volatility.
• Pair long INVX / short a more levered oilfield services peer with weaker FCF conversion for the next 3-6 months. Rationale: INVX can defend margins and deploy cash in a downturn while higher-beta peers likely see estimate cuts.
• Write cash-secured puts on INVX 10-15% below spot into the next earnings date. Thesis: monetizes elevated uncertainty while positioning for a re-rate if buybacks and the asset sale de-risk the story.
• Add to NFLX/NVDA? No action. The article does not change those names; keep capital focused on the INVX dislocation.
• If INVX rallies sharply on the Eldridge sale close, trim 25-30% and wait for the next pullback; the cleanest entry is likely before the market fully prices 2H demand uncertainty.